Cumulative Effect of the 10 Novel Genetic Variants Associated With FSS Risk
| . | FSS (%) . | Controls (%) . | . | . | . |
|---|---|---|---|---|---|
| . | N = 1163 . | N = 1071 . | . | . | . |
| Quartile of Genetic Score . | N (%) . | N (%) . | OR . | 95% CI . | P Value . |
| Quartile 1 (score ≤ 7.0) | 57 (4.9%) | 496 (46.3%) | Ref | Ref | Ref |
| Quartile 2 (7.0 < score ≤ 8.7) | 146 (12.6%) | 421 (39.3%) | 3.02 | 2.16-4.21 | < 0.0001 |
| Quartile 3 (8.7 < score ≤ 14.4) | 417 (35.9%) | 154 (14.4%) | 23.56 | 16.93-32.79 | < 0.0001 |
| Quartile 4 (score > 14.4) | 543 (64.7%) | 0 (0%) | > 999 | 0.001-999 | 0.934 |
| Cochran-Armitage trend test | < 0.0001 |
| . | FSS (%) . | Controls (%) . | . | . | . |
|---|---|---|---|---|---|
| . | N = 1163 . | N = 1071 . | . | . | . |
| Quartile of Genetic Score . | N (%) . | N (%) . | OR . | 95% CI . | P Value . |
| Quartile 1 (score ≤ 7.0) | 57 (4.9%) | 496 (46.3%) | Ref | Ref | Ref |
| Quartile 2 (7.0 < score ≤ 8.7) | 146 (12.6%) | 421 (39.3%) | 3.02 | 2.16-4.21 | < 0.0001 |
| Quartile 3 (8.7 < score ≤ 14.4) | 417 (35.9%) | 154 (14.4%) | 23.56 | 16.93-32.79 | < 0.0001 |
| Quartile 4 (score > 14.4) | 543 (64.7%) | 0 (0%) | > 999 | 0.001-999 | 0.934 |
| Cochran-Armitage trend test | < 0.0001 |
The cumulative effect was investigated in the combination of the training and testing groups. The FSS 10 novel genetic variants and their respective risk genotypes were shown in Table 1. Quartile of genetic score was calculated using the cumulation of the 10 genetic variants described in materials and methods. Abbreviations: CI, confidence interval; FSS, familial short stature; N, number; OR, odds ratio; Ref, reference.
Cumulative Effect of the 10 Novel Genetic Variants Associated With FSS Risk
| . | FSS (%) . | Controls (%) . | . | . | . |
|---|---|---|---|---|---|
| . | N = 1163 . | N = 1071 . | . | . | . |
| Quartile of Genetic Score . | N (%) . | N (%) . | OR . | 95% CI . | P Value . |
| Quartile 1 (score ≤ 7.0) | 57 (4.9%) | 496 (46.3%) | Ref | Ref | Ref |
| Quartile 2 (7.0 < score ≤ 8.7) | 146 (12.6%) | 421 (39.3%) | 3.02 | 2.16-4.21 | < 0.0001 |
| Quartile 3 (8.7 < score ≤ 14.4) | 417 (35.9%) | 154 (14.4%) | 23.56 | 16.93-32.79 | < 0.0001 |
| Quartile 4 (score > 14.4) | 543 (64.7%) | 0 (0%) | > 999 | 0.001-999 | 0.934 |
| Cochran-Armitage trend test | < 0.0001 |
| . | FSS (%) . | Controls (%) . | . | . | . |
|---|---|---|---|---|---|
| . | N = 1163 . | N = 1071 . | . | . | . |
| Quartile of Genetic Score . | N (%) . | N (%) . | OR . | 95% CI . | P Value . |
| Quartile 1 (score ≤ 7.0) | 57 (4.9%) | 496 (46.3%) | Ref | Ref | Ref |
| Quartile 2 (7.0 < score ≤ 8.7) | 146 (12.6%) | 421 (39.3%) | 3.02 | 2.16-4.21 | < 0.0001 |
| Quartile 3 (8.7 < score ≤ 14.4) | 417 (35.9%) | 154 (14.4%) | 23.56 | 16.93-32.79 | < 0.0001 |
| Quartile 4 (score > 14.4) | 543 (64.7%) | 0 (0%) | > 999 | 0.001-999 | 0.934 |
| Cochran-Armitage trend test | < 0.0001 |
The cumulative effect was investigated in the combination of the training and testing groups. The FSS 10 novel genetic variants and their respective risk genotypes were shown in Table 1. Quartile of genetic score was calculated using the cumulation of the 10 genetic variants described in materials and methods. Abbreviations: CI, confidence interval; FSS, familial short stature; N, number; OR, odds ratio; Ref, reference.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
